A rare and misdiagnosed bleeding disorder: Hereditary hemorrhagic telangiectasia

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 10, 2005, Pages 2201-2210

  Sabbà, Carlo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING DISORDER; CEREBROVASCULAR MALFORMATION; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; FAMILY HISTORY; GENE MAPPING; GENE MUTATION; HUMAN; LOW LEVEL LASER THERAPY; PRIORITY JOURNAL; PULMONARY ARTERY MALFORMATION; RARE DISEASE; RENDU OSLER WEBER DISEASE; REVIEW; SCREENING;

ARTERIOVENOUS MALFORMATIONS; HEMORRHAGE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MUTATION; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 28444474153     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01345.x     Document Type: Review

References (77)

1. Peery WH. Clinical spectrum of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Am J Med 1987; 82: 989-97.
2. Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918-24.
3. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osier-Weber syndrome). Am J Med Genet 2000; 91: 66-7.
4. Babington B. Hereditary hepistaxis. Lancet 1865; 2: 362.
5. Sutton HG. Epistaxis as an indication of impaired nutrition and of degeneration of the vascular system. Med Mirror 1864; 1: 769-81.
6. Legg JW. A case of haemophilia complicated with multiple naevi. Lancet 1876; 2: 856.
7. Rendu M. Epistaxis repetees chez un sujet porteur de petis angiomes cutanes et muqueux. Gaz Soc Hosp (Paris) 1896; 68: 1322-3.
8. Rendu M. Epistaxis repetees chez un sujet porteur de petis angiomes cutanes et muqueux. Bull Soc Med Hosp Paris 1896; 13: 731-3.
9. Osler W. On a family form of recurring epistaxis, associated with multiple telangiectases of the skin and mucous membranes. Bull Johns Hopkins Hosp 1901; 12: 243-53.
10. Osler W. On multiple telangiectases of the skin with recurring haemorrhages. QJM 1907; 1: 53-8.
11. Weber FP. Multiple hereditary developmental angiomata (telangiectases) of the skin and mucous membranes associated with recurring haemorrhages. Lancet 1907; 2: 160-2.
12. Hanes FM. Multiple hereditary telangiectases causing haemorrhage (hereditary haemorrhagic telangiectasia). Bull Johns Hopkins Hosp 1909; 20: 63-73.
13. Gibbs DD. Rendu-Osler-Weber disease: a triple eponymous title lives on. J R Soc Med 1986; 79: 742-3.
14. Goldstein HI. Hereditary hemorrhagic telangiectasia with recurring (familial) hereditary epistaxis. Arch Int Med 1921; 27: 102-25.
15. Dionigi R. Rendu-Osler disease (hereditary hemorrhagic generalized telangiectasis). Arch Med Intern 1960; 12: 67-76.
16. Report of the National Commission on Orphan Disease. Executive summary and recommendations. US Department of Health and Human Services, February 1989.
17. European Parliament and of the Council. European Commission. Decision No. 1295/1999/EC of the European Parliament and of the Council of 29 April 1999. A program of community action on rare disease within the framework for action in the field of public health (1999-2003). Official Journal L 1999; 155: 0001.
18. Smith JM. The 'pennies drop'. Genetic discoveries of medical significance. JAMA 1993; 270: 2370.
19. Lastella P, Sabba C, Lenato GM, Resta N, Lattanzi W, Gallitelli M, Cirulli A, Guanti G. Endoglin gene mutations and polymorphism in Italian patients with hereditary hemorrhagic telangiectasia. Clin Genet 2003; 63: 536-40.
20. Sabba' C, Pasculli G, Cirulli A, Gallitelli M, Virgilio G, Guastamacchia E, Resta F, Palasciano G. Rendu-Osler-Weber disease: experience with 56 patients. Ann Ital Med Int 2002; 17: 173-9.
21. Gallitelli M, Lepore V, Pasculli G, Di Gennaro L, Logroscino G, Carella A, White RI, Sabba' C. Brain abscess: A need to screen for pulmonary arteriovenous malformations. Neuroepidemiology 2004; 24: 76-8.
22. Bernard G, Mion F, Henry L, Plauchu H, Paliard P. Hepatic involvement in hereditary hemorrhagic telangiectasia: clinical, radiological and hemodynamic studies of 11 cases. Gastroenterology 1993; 105: 482-7.
23. Shovlin C, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-29.
24. Faughnan ME, Lui YW, Wirth JA, Pugash RA, Redelmeier DA, Hyland RH, White RI Jr. Diffuse pulmonary arteriovenous malformations: characteristics and prognosis. Chest 2000; 117: 31-8.
25. Vase P, Grove O. Gastrointestinal lesions in hereditary hemorrhagic telangiectasia. Gastroenterology 1986; 91: 1079-83.
26. Ingrosso M, Sabbà C, Pisani A, Principi M, Gallitelli M, Cirulli A, Francavilla A. Evidence of small-bowel involvement in hereditary hemorrhagic talengiectasia: a capsule-endoscopic study. Endoscopy 2004; 36: 1074-9.
27. Kjeldsen AD, Oxhoij H, Andersen PE, Elle B, Jacobsen JP, Vase P. Pulmonary arteriovenous malformations: screening procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia. Chest 1999; 116: 432-9.
28. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE. Endoglin, a TGF-β binding protein of endothelial cells is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-51.
29. Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995; 5: 21-8.
30. Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet 1992; 29: 527-30.
31. Gougos A, Letarte M Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line. J Immunol 1988; 141: 1934-40.
32. Letarte M, Greaves A, Vera S. CD105 (endoglin) cluster report. In: Schlossman SF, Boumsell L, Gilks W, Harlan J, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Teddez T, Todd R, eds. Leukocyte Typing V. White Cell Differentiation Antigens. Oxford: Oxford University Press, 1995: 1756-9.
33. Bühring HJ, Müller CA, Letarte M, Gougos A, Saalmüller A, van Agthoven AJ. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 1991; 5: 841-7.
34. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabeu C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992; 22: 393-7.
35. Madri JA, Bell L, Merwin JR. Modulation of vascular cell behavior by transforming growth factors beta. Mol Reprod Dev 1992; 32: 121-6.
36. ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H. Activin receptor-like kinases: a novel subclass of cell surface receptors with predicted serine/threonine kinase activity. Oncogene 1993; 8: 2879-87.
37. Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003; 3: 682-9.
38. Sanz-Rodriguez F, Fernandez LA, Zarrabertia R, Perez-Molino A, Ramirez JR, Coto E, Bernabeu C, Bolella LM. Mutation analysis in Spanish patients with hereditary hemorrhagic talengiectasia: deficient endoglin up-regulation inactivated monocytes. Clin Chem 2004; 50: 2003-11.
39. Bayrak-Toydemir P, Mao R, Lewin S, McDonald J. Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians. Genet Med 2004; 6: 175-91.
40. Shovlin CL, Hughes JM, Scott J, Seidman CE, Seidman JG. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 1997; 61: 68-79.
41. Paquet ME, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C, Letarte M. Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 2001; 10: 1347-57.
42. Cymerman U, Vera S, Karabegovic A, Abdalla S, Letarte M. Characterization of 17 novel endoglin mutations associated with hereditary hemorrhagic telangiectasia. Hum Mutat 2003; 21: 482-92.
43. Gallione CJ, Scheessele EA, Reinhardt D, Duits AJ, Berg JN, Westermann CJ, Marchuk DA. Two common endoglin mutations in families with hereditary hemorrhagic telangiectasia in the Netherlands Antilles: evidence for a founder effect. Hum Genet 2000; 107: 40-4.
44. Letteboer TG, Zewald RA, Kamping EJ, de Hass G, Mager JJ, Snijder RJ, Lindhout D, Hennekam FA, Westermann CJ, Ploos van Amstel JK. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet 2005; 116: 8-16.
45. Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE, Becker C, Letart M. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000; 156: 911-23.
46. Seki T, Hong KH, Yun J, Kim SJ, Oh SP. Isolation of a regulatory region of activin receptor-like kinase 1 gene sufficient for arterial endothelium-specific expression. Circ Res 2004; 94: 72-7.
47. van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis. Cardiovasc Res 2003; 1: 20-31.
48. Lesca G, Plauchu H, Coulet F, Lefebvre S, Plessis G, Odent S, Reviere S, Lekeup B, Goizet C, Carette MF, Cordier JF, Pinson S, Soubrier F, Calender A, Giraud S, French Rendu-Osier Network. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat 2004; 23: 289-99.
49. Wallace GM, Shovlin CL. A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin an ALK-1. Thorax 2000; 55: 685-90.
50. Cole SG, Begbie ME, Wallace GMF, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (hht3) maps to chromosome 5. J Med Gen 2005, in press.
51. Massague J, Blain SW, Lo RS. TGF-beta signaling in growth control, cancer, and heritable disorders. Cell 2000; 13: 295-309.
52. Mule KM. Role of Ras and Mapks in TGF-beta signaling. Cytokine Growth Factor Rev 2000; 11: 23-5.
53. Snyder LH, Doan CA. Clinical and experimental studies in human inheritance: is the homozygous form of multiple telangiectasia lethal? J Lab Clin Med 1944; 29: 1211-6.
54. Muller J-Y, Michailov T, Izrael V, Bernrad J. Rendu-Osler dans une grande famille saharienne. La Nouvelle Presse Med 1978; 7: 1723-5.
55. Karabegovic A, Shinawi M, Cymerman U, Letarte M. No live individual homozygous for a novel endoglin mutation was found in a consanguineous Arab family with hereditary haemorrhagic telangiectasia. J Med Genet 2004; 41: 119.
56. Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabba' C. Health related quality of life in a rare disease. HHT or Rendu-Osler-Weber disease. Qual Life Res 2004; 13: 1717-25.
57. Sabba' C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Eng J Med 2001; 345: 926.
58. Pau H, Carney AS, Murty GE. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations. Clin Otolaryngol 2001; 26: 93-8.
59. Sabba' C, Pasculli G, Cirulli A, Gallitelli M, Virgilio G, Resta F, Guastamacchia E, Palasciano G. Hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease). Minerva Cardioangiol 2002; 50: 221-38.
60. Strother CM, Newton TH. Percutaneous embolization to control epistaxis in Rendu-Osler-Weber disease. Arch Otolaryngol 1976; 102: 58-60.
61. Braverman IM, Key A, Jacobson BS. Ultrastucture and three dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990; 95: 422-7.
62. Saluja S, Henderson KJ, White RI. Embolotherapy in the bronchial and pulmonary circulation. Rad Clin North America 2000; 38: 425-45.
63. White RI, Pollak JS, Wirth JA. Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. JVIR 1996; 7: 787-804.
64. Shovlin CL, Winstock AR, Peters AM, Jackson JE, Hughes JM. Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. QJM 1995; 88: 879-87.
65. Press OW, Ramsey PG. Central nervous system infections associated with hereditary hemorrhagic telangiectasia. Am J Med 1984; 77: 86-92.
66. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M, Wheeler L. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-34.
67. Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F, Humbert M. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004; 59: 446-8.
68. Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, Pollak JS, White RI Jr. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343: 931-6.
69. Bauer T, Britton P, Wight DJ, Lomas D, Friend PJ, Alexander GJ. Liver transplantation for depatic arteriovenous malformation in hereditary hemorrhagic telangiectasia. J. Hepatol 1995; 22: 586-90.
70. Ianora AA, Memeo M, Sabba' C, Cirulli A, Rotondo A, Angelelli G. Hereditary hemorrhagic telangiectasia: multi-detector row helical CT assessment of hepatic involvement. Radiology 2004; 17: 250-9.
71. Chavan A, Caselitz M, Gratz KF, Lotz J, Kirchhoff T, Piso P, Wagner S, Manns M, Galanski M. Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations. Eur Radiol 2004; 14: 2079-85.
72. Whiting JHJR, Korzenik JR, Miller FJJR, Pollak JS, White RI. Fatal outcome after embolotherapy for hepatic arteriovenous malformations on the liver in two patients with hereditary hemorhagic telangiectasia. J Vascular Interv Radial 2000; 11: 855-8.
73. Sabba' C, Gallitelli M, Longo A, Cariati M, Angelelli G. Orthotopic liver transplantation and hereditary hemorrhagic telangiectasia: do hepatic vascular malformations relapse? A long term follow up study on two patients. J Hepatol 2004; 41: 687-9.
74. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Int Med 1999; 245: 31-9.
75. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363: 852-9.
76. Osler W. The profession of medicine. In: Verney RE, ed. The Student Life: The Philosophy of Sir William Osler. Edinburgh, UK: E. & S. Livingstone, 1957: 46.
77. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Chiefetz S, Massague J, Letarte M, Bernabeu C. Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993; 23: 2340-5.